Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BERKELEY, Calif., March 02, 2016 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company’s Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Cowen and Company Health Care Conference on Monday, March 7, 2016 at 2:40 p.m. ET.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 30 days following the presentation.
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism. For more information, visit www.xoma.com.
Company and Investor Contact: Ashleigh Barreto 510-204-7482 [email protected] Juliane Snowden The Oratorium Group, LLC [email protected] Media Contact: Ryan Flinn W2O Group 415-946-1059 [email protected]
